noom.semaglutide New weight loss program prescribes new weight loss drugs like Wegovy What is semaglutide? Exploring Ozempic,

Semaglutide is administered once weekly via subcutaneous injection, and the thigh is one of three approved injection sites alongside the abdomen and upper arm

Even under the current highest projected scenario, production of GLP-1 therapies could only cover around 100 million people. Obesity directly affects more than 1 billion people worldwide

Other companies, including Terns Pharmaceuticals (TERN-601), Structure Therapeutics (GSBR-1290), and Viking Therapeutics, have oral GLP-1 programs at earlier stages of development, but none has reached Phase 3 or generated the depth of clinical data available for orforglipron

These effects make GLP-1 weight loss therapies a potential option for individuals struggling with obesity or weight-related conditions